Adults With Upper Limb Spasticity | XEOMIN®

Adults With Upper Limb Spasticity

What's It Like Being An Adult With Upper Limb Spasticity?

Causes1-3

  • Stroke (most common cause)
  • Traumatic brain injury
  • Multiple sclerosis
  • Spinal cord problems
    (such as lesions)
  • Cerebral palsy in adults

The majority of patients treated for upper limb spasticity with XEOMIN in clinical trials were adults with post-stroke spasticity4-6

Ruben, a patient with upper limb spasticity.

Watch Ruben's story,
an adult with upper
limb spasticity treated
with XEOMIN

Manifestation

  • Spasticity may be one of many possible consequences after a stroke1
  • There are a wide range of prevalence data in post–stroke spasticity, from as little as 19% to as much as 98% of patients7,8
  • The onset of spasticity after stroke is also highly variable. It may occur shortly after the stroke or more than 1 year later9
Diagnosis of Post Stroke Upper Limb Spasticity.

Symptoms3

  • Muscle stiffness (known as hypertonia)
  • Limited range of movement
  • Reduced ability to relax muscles
  • Muscle spasms
  • Changes in limb position
  • Pain

References

  1. Spasticity, what is it? American Stroke Association website. https://www.stroke.org/en/about-stroke/effects-of-stroke/physical-effects-of-stroke/physical-impact/spasticity. Accessed November 6, 2019.
  2. Differential diagnosis for spasticity. NeuroRehab Resource website. http://www.neurorehabresource.org/Files/NRR_Differential_Diagnosis.pdf. Accessed June 17, 2019.
  3. Spasticity. American Association of Neurological Surgeons website. https://www.aans.org/Patients/Neurosurgical-Conditions-and-Treatments/Spasticity. Accessed June 17, 2019.
  4. Elovic EP, Munin MC, Kañovský P, Hanschmann A, Hiersemenzel R, Marciniak C. Randomized, placebo–controlled trial of incobotulinumtoxinA for upper–limb post–stroke spasticity. Muscle Nerve. 2016;53(3):415-421.
  5. Kañovský P, Slawek J, Denes Z, et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol. 2009;32(5):259–265.
  6. Barnes M, Schnitzler A, Medeiros L, Aguilar M, Lehnert–Batar A, Minnasch P. Efficacy and safety of NT 201 for upper limb spasticity of various etiologies—a randomized parallel-group study. Acta Neurol Scand. 2010;122(4):295–302.
  7. Wissel J, Schelosky LD, Scott J, Christe W, Faiss JH, Mueller J. Early development of spasticity following stroke: a prospective, observational trial. J Neurol. 2010;257(7):1067–1072.
  8. Ward AB. A literature review of the pathophysiology and onset of post–stroke spasticity. Eur J Neurol. 2012;19(1):21–27.
  9. Wissel J, Manack A, Brainin M. Toward an epidemiology of poststroke spasticity. Neurology. 2013;80(3 suppl 2):S13–S19.